Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs

International Journal of Pharmaceutics

Volumn 395, Issue 1-2, 2010, Pages 281-289

  Galmarini, Carlos M ^b   Warren, Galya ^a   Senanayake, Madapathage T ^a   Vinogradov, Serguei V ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Univ Claude Bernard   (France)

Author keywords

Cationic nanogels; Drug resistance; Nucleoside 5' triphosphate; Nucleoside analogs; Tumor targeting peptides; Xenograft tumor model

Indexed keywords

CYTARABINE; GEMCITABINE; NANOCARRIER; NUCLEOSIDE ANALOG; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG CARRIER; GEL; NANOPARTICLE; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GEL; IC50; MEDICINAL CHEMISTRY; METABOLISM; NANOTECHNOLOGY; NUDE MOUSE; PHARMACEUTICS; PHOSPHORYLATION; PROCEDURES; TIME; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BIOLOGICAL TRANSPORT; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; CYTARABINE; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG RESISTANCE; DRUG RESISTANCE, NEOPLASM; GELS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; NANOTECHNOLOGY; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 22; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954309207     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.05.028     Document Type: Article

References (39)

1. Das M., Mohanty C., Sahoo S.K. Ligand-based targeted therapy for cancer tissue. Expert Opin. Drug Deliv. 2009, 6:285-304.
2. Diab R., Degobert G., Hamoudeh M., Dumontet C., Fessi H. Nucleoside analogue delivery systems in cancer therapy. Expert Opin. Drug Deliv. 2007, 4:513-531.
3. Ewald B., Sampath D., Plunkett W. Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene 2008, 27:6522-6537.
4. Fogal V., Zhang L., Ruoslahti E. Mitochondrial/cell surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res. 2008, 68:7210-7218.
5. Fraternale A., Casabianca A., Rossi L., Chiarantini L., Brandi G., Aluigi G., Schiavano G.F., Magnani M. Inhibition of murine AIDS by combination of AZT and dideoxycytidine 5'-triphosphate. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1996, 12:164-173.
6. Galmarini C.M., Jordheim L., Dumontet C. Pyrimidine nucleoside analogs in cancer treatment. Expert Rev. Anticancer Ther. 2003, 3:717-728.
7. Galmarini C.M., Clarke M.L., Jordheim L., Santos C.L., Cros E., Mackey J.R., Dumontet C. Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol. 2004, 4:8.
8. Galmarini C.M., Popowycz F., Joseph B. Cytotoxic nucleoside analogues: different strategies to improve their clinical efficacy. Curr. Med. Chem. 2008, 15:1072-1082.
9. Galmarini C.M., Warren G., Kohli E., Zeman A., Mitin A., Vinogradov S.V. Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines. Mol. Cancer Ther. 2008, 7:3373-3380.
10. Giovannetti E., Laan A.C., Vasile E., Tibaldi C., Nannizzi S., Ricciardi S., Falcone A., Danesi R., Peters G.J. Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. Nucleosides Nucleotides Nucleic Acids 2008, 27:705-720.
11. Hillaireau H., Le Doan T., Appel M., Couvreur P. Hybrid polymer nanocapsules enhance in vitro delivery of azidothymidine-triphosphate to macrophages. J. Control. Release 2006, 116:346-352.
12. Hillaireau H., Le Doan T., Chacun H., Janin J., Couvreur P. Encapsulation of mono- and oligo-nucleotides into aqueous-core nanocapsules in presence of various water-soluble polymers. Int. J. Pharm. 2007, 331:148-152.
13. Huber-Ruano I., Pastor-Anglada M. Transport of nucleoside analogs across the plasma membrane: a clue to understanding drug-induced cytotoxicity. Curr. Drug Metab. 2009, 10:347-358.
14. Jordheim L., Galmarini C.M., Dumontet C. Drug resistance to cytotoxic nucleoside analogues. Curr. Drug Targets 2003, 4:443-460.
15. Jordheim L.P., Cros E., Gouy M.H., Galmarini C.M., Peyrottes S., Mackey J., Perigaud C., Dumontet C. Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug. Clin. Cancer Res. 2004, 10:5614-5621.
16. Jordheim L.P., Galmarini C.M., Dumontet C. Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells. Cancer Chemother. Pharmacol. 2006, 58:547-554.
17. Karmali P.P., Kotamraju V.R., Kastantin M., Black M., Missirlis D., Tirrell M., Ruoslahti E. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine 2009, 5:73-82.
18. Kohli E., Han H.Y., Zeman A.D., Vinogradov S.V. Formulations of biodegradable Nanogel carriers with 5'-triphosphates of nucleoside analogs that display a reduced cytotoxicity and enhanced drug activity. J. Control. Release 2007, 21:19-27.
19. Laakkonen P., Porkka K., Hoffman J.A., Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat. Med. 2002, 8:751-755.
20. Lutsenko S.V., Feldman N.B., Severin S.E. Cytotoxic and antitumor activities of doxorubicin conjugates with the epidermal growth factor and its receptor-binding fragment. J. Drug Target. 2002, 10:567-571.
21. Luo G., Yu X., Jin C., Yang F., Fu D., Long J., Xu J., Zhan C., Lu W. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. Int. J. Pharm. 2009, (epub October 13).
22. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65:271-284.
23. Makarov E., Gerson T., Poluektova L., Vinogradov S.V. Efficient suppression of human immunodeficiency virus in macrophages by Nano-NRTIs 2009, 92.
24. Meier C., Balzarini J. Application of the cycloSal-prodrug approach for improving the biological potential of phosphorylated biomolecules. Antiviral Res. 2006, 7:282-292.
25. Nori A., Kopecek J. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv. Drug Deliv. Rev. 2005, 57:609-636.
26. Oussoren C., Magnani M., Fraternale A., Casabianca A., Chiarantini L., Ingebrigsten R., Underberg W.J., Storm G. Liposomes as carriers of the antiretroviral agent dideoxycytidine-5'-triphosphate. Int. J. Pharm. 1999, 180:261-270.
27. Pestieau S.R., Stuart O.A., Chang D., Jacquet P., Sugarbaker P.H. Pharmacokinetics of intraperitoneal gemcitabine in a rat model. Tumori 1998, 84:706-711.
28. Peyrottes S., Egron D., Lefebvre I., Gosselin G., Imbach J.L., Périgaud C. SATE pronucleotide approaches: an overview. Mini Rev. Med. Chem. 2004, 4:395-408.
29. Saiyed Z.M., Gandhi N.H., Nair M.P. AZT 5'-triphosphate nanoformulation suppresses human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells. J. Neurovirol. 2009, 2:1-5.
30. Twentyman P.R., Fox N.E., Rees J.K. Chemosensitivity testing of fresh leukaemia cells using the MTT colorimetric assay. Br. J. Haematol. 1989, 71:19-24.
31. Ullman B. Dideoxycytidine metabolism in wild type and mutant CEM cells deficient in nucleoside transport or deoxycytidine kinase. Adv. Exp. Med. Biol. 1989, 253B:415-420.
32. Vinogradov S.V., Bronich T.K., Kabanov A.V. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv. Drug Deliv. Rev. 2002, 54:135-147.
33. Vinogradov S.V., Batrakova E.V., Kabanov A.V. Nanogels for oligonucleotide delivery to the brain. Bioconjug. Chem. 2004, 15:50-60.
34. Vinogradov S.V., Zeman A.D., Batrakova E.V., Kabanov A.V. Polyplex Nanogel formulations for drug delivery of cytotoxic nucleoside analogs. J. Control. Release 2005, 107:143-157.
35. Vinogradov S.V., Kohli E., Zeman A.D. Cross-linked polymeric nanogel formulations of 5'-triphosphates of nucleoside analogues: role of the cellular membrane in drug release. Mol. Pharm. 2005, 2:449-461.
36. Vinogradov S.V., Kohli E., Zeman A.D. Comparison of nanogel drug carriers and their formulations with nucleoside 5'-triphosphates. Pharm. Res. 2006, 23:920-930.
37. Vinogradov S.V., Kohli E., Zeman A., Kabanov A.V. Chemical engineering of nanogel drug carriers: increased bioavailability and decreased cytotoxicity. Polymer Prepr. (ACS) 2006, 47:27-28.
38. Vinogradov S.V. Polymeric nanogel formulations of nucleoside analogs. Expert Opin. Drug Deliv. 2007, 4:5-17.
39. Vinogradov S.V., Mitin A., Warren G. Folate-targeted polyformulations of cytotoxic nucleoside triphosphates and paclitaxel. Polymer Prepr. (ACS) 2008, 49:1050-1051.